ResMed Inc (RMD)
Return on assets (ROA)
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | 1,400,723 | 1,313,254 | 1,248,705 | 1,112,883 | 1,020,950 | 958,378 | 890,386 | 906,500 | 897,556 | 862,953 | 809,465 | 786,302 | 779,437 | 779,474 | 521,981 | 499,744 | 474,503 | 457,240 | 698,858 | 679,898 |
Total assets | US$ in thousands | 8,174,390 | 7,566,820 | 7,141,330 | 7,222,420 | 6,872,390 | 6,814,560 | 6,905,090 | 6,740,790 | 6,751,710 | 6,713,880 | 6,676,100 | 5,177,560 | 5,095,850 | 4,905,260 | 4,734,740 | 4,729,170 | 4,728,120 | 4,585,720 | 4,572,860 | 4,620,840 |
ROA | 17.14% | 17.36% | 17.49% | 15.41% | 14.86% | 14.06% | 12.89% | 13.45% | 13.29% | 12.85% | 12.12% | 15.19% | 15.30% | 15.89% | 11.02% | 10.57% | 10.04% | 9.97% | 15.28% | 14.71% |
June 30, 2025 calculation
ROA = Net income (ttm) ÷ Total assets
= $1,400,723K ÷ $8,174,390K
= 17.14%
The analysis of ResMed Inc.'s return on assets (ROA) over the specified period reveals a generally upward trend, reflecting improving efficiency in generating profits from its asset base. Starting from a ROA of 14.71% as of September 30, 2020, the metric experienced a slight increase, reaching 15.28% by December 31, 2020. However, a notable decline occurred in 2021, with ROA falling to 9.97% by March 31, 2021, and subsequently fluctuating between approximately 10% and 11% during the rest of 2021.
Throughout 2022, resumption of positive momentum is observed, with ROA climbing back to around 15.89% at the end of March 2022 and maintaining values in the vicinity of 15% through mid-2022. The latter part of 2022 indicates a slight decline, with ROA decreasing to roughly 12.12% by December 2022. The year 2023 shows stabilization at levels slightly above 12%, with a modest gradual increase, culminating at 13.45% as of September 30, 2023.
Entering 2024, ResMed's ROA trends upward again, reaching 14.06% by the end of March and 14.86% at the end of June, further improving to 15.41% by September 2024. The data extending into the first half of 2025 indicates continued growth, with ROA reaching 17.49% on December 31, 2024, and remaining robust at 17.36% in March 2025 before a slight decline to 17.14% in June 2025.
Overall, the ROA pattern suggests periods of temporary decline aligned with external or internal factors but shows resilience and an upward trajectory in recent periods, indicative of enhanced asset efficiency and profitability. The upward momentum particularly from late 2023 onward signals a positive outlook in asset utilization and operational performance.
Peer comparison
Jun 30, 2025